SavedAdd your journal

Journals / Bozok Tıp Dergisi / 2026 / Cilt: 16 Sayı: 3

SH3PXD2A LEVELS IN ALZHEIMER’S DISEASE: AN EXPLORATORY STUDY OF A POTENTIAL SYNAPTIC BLOOD BIOMARKER

Alzheimer Hastalığında SH3PXD2A Düzeyleri: Potansiyel Bir Sinaptik Kan Biyobelirteci Üzerine Keşifsel Bir Çalışma

Tugba Agbektas(SIVAS CUMHURIYET UNIVERSITY)0009-0004-4533-0019
Zuhal Tunçbilek(SIVAS CUMHURIYET UNIVERSITY)0000-0002-6510-0884
Taylan Yavuz Bulut(NIGDE OMER HALISDEMIR UNIVERSITY)0000-0002-6709-6647
Ayça Taş(SIVAS CUMHURIYET UNIVERSITY)0000-0002-7132-1325
Yavuz Siliğ(SIVAS CUMHURIYET UNIVERSITY)0000-0002-0562-7457
Pages
571–580
Publication Date
2026-09-25
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Larger longitudinal studies incorporating detailed clinical characterization and mechanistic investigations are needed to determine its biological and clinical relevance.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Alzheimer’s d isease ( AD) i s a progressive neurodegenerative disorder wi th incompletely understood molecular mechanisms.
📊
Key Findings & Data:This study examined plasma SH3 and PX domains 2A (SH3PXD2A) concentrations in patients with AD, as this protein has not previously been directly investigated in AD or other neurodegenerative disorders.
💡
Conclusion & Impact:Larger longitudinal studies incorporating detailed clinical characterization and mechanistic investigations are needed to determine its biological and clinical relevance.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Alzheimer Hastalığı · SH3PXD2A · Nörodejenerasyon

Abstract

Objective: Alzheimer’s d isease ( AD) i s a progressive neurodegenerative disorder wi th incompletely understood molecular mechanisms. This study examined plasma SH3 and PX domains 2A (SH3PXD2A) concentrations in patients with AD, as this protein has not previously been directly investigated in AD or other neurodegenerative disorders. Material and Methods: A total of 45 patients w ith A D a nd 4 5 healthy controls were i ncluded. Plasma SH3PXD2A concentrations were measured using a commercial immunoenzymatic assay, and absorbance was recorded at 450 nm using a microplate spectrophotometer. Demographic variables, including age and gender, were also assessed. Results: Gender distribution was comparable between groups; however, participants wi th AD were significantly o lder t han controls. P lasma SH3PXD2A concentrations were significantly hig her in the AD group. In multivariable logistic regression analysis, bo th age an d pl asma SH3PXD2A concentration were independently associated with AD status. ROC analysis indicated moderate discriminatory performance for SH3PXD2A, with an area under the curve of 0.761 (95% CI: 0.657-0.866; p<0.001). A cut-off value of ≥3.120 ng/mL yielded 55.6% sensitivity and 97.8% specificity. The difference in SH3PXD2A concentrations remained significant after adjustment for age. Conclusion: Plasma SH3PXD2A concentrations were elevated in patients with AD and were independently associated with AD status after age adjustment. SH3PXD2A may represent a potential blood-based biomarker candidate in AD. Larger longitudinal studies incorporating detailed clinical characterization and mechanistic investigations are needed to determine its biological and clinical relevance.

Özet

Amaç: Alzheimer hastalığı (AH), moleküler mekanizmaları henüz tam olarak açıklığa kavuşmamış, ilerleyici bir nörodejeneratif hastalıktır. Bu çalışmada, SH3 ve PX domainleri 2A (SH3PXD2A) proteininin AH veya diğer nörodejeneratif hastalıklarda daha önce doğrudan araştırılmamış olması nedeniyle, AH hastalarında plazma SH3PXD2A konsantrasyonları incelendi. Gereç ve Yöntemler: Çalışmaya 45 AH hastası ve 45 sağlıklı kontrol dahil edildi. Plazma SH3PXD2A konsantrasyonları ticari bir immünoenzimatik analiz yöntemi ile ölçüldü ve absorbans değerleri mikroplaka spektrofotometresi kullanılarak 450 nm’de kaydedildi. Yaş ve cinsiyet dahil olmak üzere demografik değişkenler de değerlendirildi. Bulgular: Gruplar arasında cinsiyet dağılımı benzerdi; ancak AH grubundaki katılımcılar kontrol grubuna göre anlamlı olarak daha yaşlıydı. Plazma SH3PXD2A konsantrasyonları AH grubunda anlamlı derecede daha yüksekti. Çok değişkenli lojistik regresyon analizinde, hem yaş hem de plazma SH3PXD2A konsantrasyonu AH varlığı ile bağımsız olarak ilişkili bulundu. ROC analizi, SH3PXD2A’nın AH hastalarını kontrollerden ayırt etmede orta düzeyde performans gösterdiğini ortaya koydu [eğri altında kalan alan=0,761; %95 güven aralığı: 0,657-0,866; p<0,001]. ≥3,120 ng/mL kesim değeri için duyarlılık %55,6, özgüllük %97,8 olarak belirlendi. Yaşa göre düzeltme yapıldıktan sonra da gruplar arasındaki SH3PXD2A konsantrasyonu farkı anlamlılığını korudu. Sonuç: Plazma SH3PXD2A konsantrasyonları AH hastalarında yükselmiş olup, yaş için düzeltme sonrasında da AH varlığı ile bağımsız ilişki göstermiştir. SH3PXD2A, AH için potansiyel kan temelli bir biyobelirteç adayı olabilir. Biyolojik ve klinik öneminin belirlenmesi için ayrıntılı klinik değerlendirmeler ve mekanistik analizler içeren daha büyük, uzunlamasına çalışmalara ihtiyaç vardır.

🔖

Cite This Article

Agbektas, T., Tunçbilek, Z., Bulut, T. Y., Taş, A., Siliğ, Y. (2026). SH3PXD2A LEVELS IN ALZHEIMER’S DISEASE: AN EXPLORATORY STUDY OF A POTENTIAL SYNAPTIC BLOOD BIOMARKER. Bozok Tıp Dergisi, Cilt: 16 Sayı: 3, 571–580. https://doi.org/10.16919/bozoktip.1980590

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (40)

  1. Alzheimer’s Disease International. World Alzheimer Report 2022: Life after diagnosis: Navigating treatment, care and support. London: Alzheimer’s Disease International; 2022. Available from: https://www.alzint.org/resource/world-alzheimer-report-2022/
  2. Apostolova LG. Alzheimer disease. Continuum (Minneap Minn). 2016;22(2 Dementia):419-34.
  3. Safiri S, Ghaffari Jolfayi A, Fazlollahi A, Morsali S, Sarkesh A, Daei Sorkhabi A, et al. Alzheimer's disease: A comprehensive review of epidemiology, risk factors, symptoms, diagnosis, management, caregiving, advanced treatments and associated challenges. Front Med (Lausanne). 2024;11:1474043.
  4. Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120(3):885-90.
  5. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82(12):4245-9.
  6. Goedert M, Spillantini MG, Crowther RA. Tau proteins and neurofibrillary degeneration. Brain Pathol. 1991;1(4):279-86.
  7. Therriault J, Schindler SE, Salvadó G, Pascoal TA, Benedet AL, Ashton NJ, et al. Biomarker-based staging of Alzheimer disease: Rationale and clinical applications. Nat Rev Neurol. 2024;20(4):232-44.
  8. Parker TD, Cash DM, Lane CA, Lu K, Malone IB, Nicholas JM, et al. Hippocampal subfield volumes and pre-clinical Alzheimer’s disease in 408 cognitively normal adults born in 1946. PLoS One. 2019;14(10):e0224030.
  9. Beyreuther K, Masters CL. Amyloid precursor protein and beta A4 amyloid in the etiology of Alzheimer's disease. Brain Pathol. 1991;1(4):241-51.
  10. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991;12:383-8.
  11. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991;6(4):487-98.
  12. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325(6106):733-6.
  13. Gunawardena S, Yang G, Goldstein LS. Presenilin controls kinesin-1 and dynein function during APP-vesicle transport in vivo. Hum Mol Genet. 2013;22(19):3828-43.
  14. Sokol DK, Lahiri DK. Alzheimer’s drugs, APPlication for Down syndrome? Ageing Res Rev. 2024;96:102281.
  15. Li CMC, Jacks T. SH3PXD2A (SH3 and PX domains 2A). Atlas Genet Cytogenet Oncol Haematol. 2017. Available from: https://atlasgeneticsoncology.org/gene/45995/sh3pxd2a-(sh3-and-px-domains-2a)
  16. Lock P, Abram CL, Gibson T, Courtneidge SA. A new method for isolating tyrosine kinase substrates used to identify fish, an SH3 and PX domain-containing protein, and Src substrate. EMBO J. 1998;17(15):4341-51.
  17. Burger KL, Learman BS, Boucherle AK, Sirintrapun SJ, Isom S, Diaz B, et al. The podosome marker protein Tks5 regulates macrophage invasive behavior. Cell Motil Cytoskeleton. 2011;68(12):694-711.
  18. Thompson O, Moore CJ, Hussain SA, Rezniczek GA, Jockusch BM, Winder SJ. Dystroglycan, Tks5 and Src mediated assembly of podosomes in myoblasts. PLoS One. 2008;3(11):e3638.
  19. Murphy DA, Courtneidge SA. The “ins” and “outs” of podosomes and invadopodia: Characteristics, formation and function. Nat Rev Mol Cell Biol. 2011;12(7):413-26.
  20. Oikawa T, Itoh T, Itoh T, Stewart-Hutchinson PJ, Snapper SB, Takenawa T. Tks5-dependent formation of circumferential podosomes/invadopodia mediates cell-cell fusion. J Cell Biol. 2012;197(4):553-68.
  21. Santiago-Medina M, Gregus KA, Gomez TM. Regulation of ECM degradation and axon guidance by growth cone invadosomes. Development. 2015;142(3):486-96.
  22. Van der Auwera S, Ameling S, Wittfeld K, Frenzel S, Bülow R, Nauck M, et al. Circulating microRNA miR-425-5p
  23. associated with brain white matter lesions and inflammatory processes. Int J Mol Sci. 2024;25(2):887.
  24. Armstrong NJ, Mather KA, Sargurupremraj M, Knol MJ, Malik R, Satizabal CL, et al. Common genetic variation indicates separate causes for periventricular and deep white matter hyperintensities. Stroke. 2020;51(7):2111-21.
  25. Islam T, Rahman MR, Khan A, Moni MA. Integration of Mendelian randomisation and systems biology models to identify novel blood-based biomarkers for stroke. J Biomed Inform. 2023;141:104345.
  26. Laumet G, Petitprez V, Rollin-Sillaire A, Ayral AM, Hansmannel F, Chapuis J, et al. A study of the association between the ADAM12 and SH3PXD2A (SH3MD1) genes and Alzheimer’s disease. Neurosci Lett. 2010;468(1):1-2. Hirakawa H, Terao T. The genetic association between bipolar disorder and dementia: A qualitative review. Front Psychiatry. 2024;15:1414776.
  27. Bertram L, Blacker D, Mullin K, Keeney D, Jain S, Bassett S, et al. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science. 2000;290(5500):2302-3.
  28. Aarsland D, Sunde AL, Tovar-Rios DA, Leuzy A, Fladby T, Zetterberg H, et al. Prevalence of Alzheimer’s disease pathology in the community. Nature. 2026;650(8100):182-6.
  29. Zhang XX, Tian Y, Wang ZT, Ma YH, Tan L, Yu JT. The epidemiology of Alzheimer's disease modifiable risk factors and prevention. J Prev Alzheimers Dis. 2021;8(3):313-21.
  30. Almutairi JA, Kidd EJ. Biological sex disparities in Alzheimer's disease. Curr Top Behav Neurosci. 2025;69:79-104.
  31. Huque H, Eramudugolla R, Chidiac B, Ee N, Ehrenfeld L, Matthews FE, et al. Could country-level factors explain sex differences in dementia incidence and prevalence? A systematic review and meta-analysis. J Alzheimers Dis. 2023;91(4):1231-41.
  32. O’Neal MA. Women and the risk of Alzheimer's disease. Front Glob Womens Health. 2024;4:1324522.
  33. Jiang G, Xie G, Li X, Xiong J. Cytoskeletal proteins and Alzheimer’s disease pathogenesis: Focusing on the interplay with tau pathology. Biomolecules. 2025;15(6):831.
  34. Haseena PA, Basavaraju N, Gupta A, Kommaddi RP. Actin cytoskeleton at the synapse: An Alzheimer's disease perspective. Cytoskeleton (Hoboken). 2026;83(1):15-28.
  35. Malinin NL, Cao L, Seals DF, Courtneidge SA. Amyloid-beta neurotoxicity is mediated by FISH adapter protein and ADAM12 metalloprotease activity. Proc Natl Acad Sci U S A. 2005;102(8):3058-63.
  36. Harold D, Peirce T, Moskvina V, Myers A, Jones L, Hamshere M, et al. Interaction between the ADAM12 and SH3MD1 genes may confer susceptibility to late-onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(4):448-52.
  37. Teasdale RD, Collins BM. Insights into the PX domain and sorting nexin protein families: Structures, functions and roles in disease. Biochem J. 2012;441(1):39-59.
  38. Nixon RA, Rubinsztein DC. Mechanisms of autophagy-lysosome dysfunction in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2024;25(11):926-46.
  39. Phillips ETJ, Maguire EJ. Phosphoinositides: Roles in the development of microglial-mediated neuroinflammation and neurodegeneration. Front Cell Neurosci. 2021;15:652593.
  40. Ando K, Brion JP, Stygelbout V, Suain V, Authelet M, Dourlen P, et al. Dysregulation of phosphoinositide 5-phosphatases and phosphoinositides in Alzheimer's disease. Front Aging Neurosci. 2021;15:614855.